Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 4, 2007, Pages 365-370

  Rooth, Elisabeth ^a   Wallen, Hakan ^a   Antovic, Alexandra ^b   Von Arbin, Magnus ^a   Kaponides, Georgios ^c   Wahlgren, Nils ^c   Blombäck, Margareta ^b   Antovic, Joven ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fibrinolysis; Inflammation; Ischemic stroke; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; HEMOSTATIC AGENT; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VON WILLEBRAND FACTOR;

ACUTE DISEASE; ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; FEMALE; FIBRINOLYSIS; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE PATIENT;

ACUTE-PHASE REACTION; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CARBOXYPEPTIDASE U; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 34247891640     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3281139c34     Document Type: Article

References (34)

1. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86:366-373.
2. Warlow C, Dennis MS, van Gijn J, Hankey GJ, Sandercock P, Bamford J, Wardlaw JM. Stroke. A practical guide to management. Oxford: Blackwell; 1996.
3. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 1996; 27:1296-1300.
4. Yamazaki M, Uchiyama S, Maruyama S. Alterations of haemostatic markers in various subtypes and phases of stroke. Blood Coagul Fibrinolysis 1993; 4:707-712.
5. Cushman M. Hemostatic risk factors for cardiovascular disease. Hematology 1999; 4:236-242.
6. Cherian P. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003; 34:2132-2137.
7. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Olsson T. Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. Stroke 1998; 29:2261-2267.
8. Happaniemi E, Soinne L, Syrjälä M, Kaste M, Tatlisumak T. Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke. Acta Neurol Scand 2004; 110:242-247.
9. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96:2534-2538.
10. Bajzar L, Manuel R, Neisheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270:1477-1484.
11. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272:14477-14482.
12. Wang W, Boffa MB, Bajzar L, Walker JB, Neisheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181.
13. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22:867-873.
14. Juhan-Vague I, Morange PE, PRIME Study Group. Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. J Thromb Haemost 2003; 1:2243-2244.
15. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88:1020-1025.
16. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84:364-368.
17. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165:1053-1058.
18. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34:1038-1040.
19. Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34:2387-2391.
20. Leebeek FWG, Van Goor MLPJ, Guimaraes AHC, Brouwers GJ, De Maat MP, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3:2211-2218.
21. Faber CG, Lodder J, Kessels F, Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol Haemost Thromb 2003; 33:52-58.
22. Reganon E, Vila V, Martinez-Sales V, Vaya A, Lago A, Alonso P, Aznar J. Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb Res 2003; 112:217-221.
23. He S, Bremme K, Blombäck M. A laboratory method for determination of Overall hemostatic potential in plasma. Method design and preliminary results. Thromb Res 1999; 96:145-156.
24. He S, Antovic A, Blomback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103:355-361.
25. Antovic A, Blomback M, Bremme K, Van Rooijen M, He S. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost 2003; 1:2531-2535.
26. Antovic JP, Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost 2003; 90:620-627.
27. Antovic JP, Antovic A, Sten-Linder M, Wramsby M, Blomback M. Overall hemostatic potential (OHP) assay - a possible tool for determination of prothtrombotic pattern in FXII deficiency. J Thromb Haemost 2004; 2:2058-2060.
28. Antovic JP, Antovic A, He S, Tengborn L, Blomback M. Overall haemostatic potential (OHP) method can be used for estimation of thrombin activatable fibrinolysis inhibitor (TAFI) dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to FVIII. Haemophilia 2002; 8:781-786.
29. Antovic A, Blomback M, Bremme K, He S. The assay of overall haemostasis potential used to monitor low molecular mass (weight) heparin, dalteparin treatment in pregnant women with previous thromboembolism. Blood Coagul Fibrinolysis 2002; 13:181-186.
30. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35-41.
31. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS - system for mixed models. Cary, NC: SAS Institute Inc; 1996.
32. Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen NH, Jorneskog G, Blomback M. Thrombin activatable fibrinolysis inhibitor [TAFI] and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis 2003; 14:551-556.
33. Guimares AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124:659-665.
34. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31:26-32.